Obesity mkt grows larger than ever...Saxenda leads mkt
By Chon, Seung-Hyun | translator Kim, Jung-Ju
23.03.02 14:30:18
가나다라
0
Obesity drug market KRW 175.7 billion last year...renews record for 4 consecutive years
Saxenda’s sales rise 63% from the previous year to record KRW 58.9 billion...its market share increases from 25% to 35%
Sales gap between Saxenda and Qsymia widen from KRW 10 billion to KRW 28.8 billion
The domestic obesity treatment market grew to record an all-time high last year. Saxenda maintained its unrivaled lead for 4 consecutive years and left its competitor Qsymia far behind.
According to the market research institution IQVIA on the 2nd, the obesity treatment market grew 22.4% YoY to reach KRW 175.7 billion last year. The obesity treatment market had renewed its record for 4 consecutive years since it first set a 10-year new record of KRW 134.1 billion in 2019. The market, which had recorded KRW 96.8 billion in 2018, had recorded high annual growth of 81.5% for the 4 years that followed.
However, this growth in the obesity treatment market had slowed down with the spread of COVID
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)